This invention provides novel carbonic anhydrase (CAIX) nucleic acid and peptidesequences, as well as related methods and compositions, including anti-cancerimmunogenic agent(s) (e.g. vaccines and chimeric molecules) that elicit animmune response specifically directed against cancer cells expressing a CAIXantigenic marker. The novel CAIX variant and related compositions are usefulin a wide variety of treatment modalities including, but not limited to proteinvaccination, DNA vaccination, and adoptive immunotherapy.
